Rapid-acting IM ziprasidone in a psychiatric emergency service: A naturalistic study

General Hospital Psychiatry

Volumn 27, Issue 2, 2005, Pages 140-144

  Preval, Horacio ^a   Klotz, Steven G ^a   Southard, Robert ^a   Francis, Andrew ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Atypical antipsychotics; Emergency psychiatry; Intramuscular; Neuroleptics; Ziprasidone

Indexed keywords

CHLORPROMAZINE; DIPHENHYDRAMINE; HALOPERIDOL; LORAZEPAM; NEUROLEPTIC AGENT; ZIPRASIDONE;

ADULT; AGED; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DYSTONIA; ELECTROCARDIOGRAM; EMERGENCY HEALTH SERVICE; FEMALE; HUMAN; IMMOBILIZATION; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH SERVICE; MENTAL PATIENT; QT PROLONGATION; RATING SCALE; RESTLESSNESS; SCORING SYSTEM;

EID: 14844307636     PISSN: 01638343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2004.11.004     Document Type: Article

References (11)

1. G.W. Currier, and A. Trenton Pharmacological treatment of psychotic agitation CNS Drugs 16 2002 219 228
2. S. Brook, J.V. Lucey, and K.P. Gunn Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis J. Clin. Psychiatry 61 2000 933 941
3. D.G. Daniel, S.G. Potkin, K.R. Reeves, R.H. Swift, and E.P. Harrigan Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial Psychopharmacology 155 2001 128 134
4. M.D. Lesem, J.M. Zajecka, R.H. Swift, K.R. Reeves, and E.P. Harrigan Intramuscular ziprasidone 2 mg versus 10 mg, in the short-term management of agitated psychotic patients J. Clin. Psychiatry 62 2001 12 18
5. Brook S, Walden J, Benattia I, Siu CO, Romano SJ. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: Comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology [in press].
6. J.H. Shale, C.M. Shale, and W.D. Mastin A review of the safety and efficacy of droperidol for the rapid sedation of severely agitated and violent patients J. Clin. Psychiatry 64 2003 500 505
7. R.H. Swift, E.P. Harrigan, and J.C. Cappelleri Validation of the behavioral activity rating scale (BARS™): a novel measure of activity in agitated patients J. Psychiatr. Res. 36 2002 87 95
8. P. Wright, M. Birkett, and S.R. David Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia Am. J. Psychiatry 158 2001 1149 1151
9. A. Breier, K. Meehan, M. Birkett, S. David, I. Ferchland, and V. Sutton A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia Arch. Gen. Psychiatry 59 2002 441 448
10. S. Kasper, M.N. Lerman, and R.D. McQuade Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia Int. J. Neuropsychopharmacol. (England) 6 2003 325 337
11. J.M. Kane, W.H. Carson, and A.R. Saha Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder J. Clin. Psychiatry 63 2002 763 771